CHIP is by definition incidentally identified, but carries risks for subsequent development of myeloid neoplasms (e.g. MDS, AML), as well as nonneoplastic morbidities (e.g. cardiovascular events); however, the magnitude of risk is dependent on multiple factors, such as the specific gene mutation type, VAF, or prior exposure to DNA‐damaging agents (e.g. solid tumour treatment). This evidence concerns the gene STUB1 and myeloid neoplasm.